Preferred Label : Fanconi anemia, complementation group a;
Symbol : FANCA;
CISMeF acronym : FA; FANCA;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Fanconi anemia; FA;
Included titles and symbols : Fanconi anemia, estren-dameshek variant; Estren-dameshek variant of fanconi anemia; Estren-dameshek variant of fanconi pancytopenia;
Description : Fanconi anemia is a clinically and genetically heterogeneous disorder that causes
genomic instability. Characteristic clinical features include developmental abnormalities
in major organ systems, early-onset bone marrow failure, and a high predisposition
to cancer. The cellular hallmark of FA is hypersensitivity to DNA crosslinking agents
and high frequency of chromosomal aberrations pointing to a defect in DNA repair (summary
by Deakyne and Mazin, 2011). Soulier et al. (2005) noted that the FANCA, -C, -E, -F,
-G, and -L proteins are part of a nuclear multiprotein core complex which triggers
activating monoubiquitination of the FANCD2 protein during S phase of the growth cycle
and after exposure to DNA crosslinking agents. The FA/BRCA pathway is involved in
the repair of DNA damage. Some cases of Fanconi anemia have presented with a VACTERL
(192350) or;
Inheritance : Autosomal recessive;
Molecular basis : Caused by mutation in the Fanconi anemia, complementation group A gene (FANCA, 607139.0001);
Laboratory abnormalities : Multiple chromosomal breaks; Chromosomal breakage induced by diepoxybutane (DEB), and mitomycin C; Deficient excision of UV-induced pyrimidine dimers in DNA; Prolonged G2 phase of cell cycle;
Prefixed ID : #227650;
Origin ID : 227650;
UMLS CUI : C3469521;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Related ORDO disease(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to NTBT